Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies. This partnership enables SignalChem Biotech to incorporate these AI-designed protein technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use.
The agreement expands SignalChem’s specialized contract research organization (CRO) capabilities and supports Sino Biological’s broader strategy of integrating AI-enabled technologies across its global life science tools and services portfolio. By leveraging Monod Bio’s LuxSit luciferase and NovoBodies, researchers can obtain high-quality discovery candidates more rapidly, addressing complex biological questions and advancing research programs efficiently, according to Dr. Rob Burgess, Chief Business Officer of Sino Biological.
Monod Bio’s LuxSit is an AI-designed luciferase engineered for robust luminescent biosensors, while its NovoBodies are compact, highly stable binding proteins engineered for high-performance recognition of various targets. Together, these technologies provide versatile tools for developing customized assays and discovery workflows. Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio, emphasized that SignalChem Biotech and Sino Biological have the scientific expertise, customer reach, and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of Monod Bio’s platform and reinforces the value of its Monod Inside model for integrating AI-designed proteins into commercial products and services.
SignalChem Biotech, a wholly owned subsidiary of Sino Biological Inc., provides specialized reagents and CRO services supporting drug discovery and life science research. Sino Biological is an international life science tools provider with facilities across Asia, North America, and Europe. The collaboration is expected to enhance the companies’ offerings in the life science tools market, leveraging AI-designed proteins to meet evolving research needs.
The development of the related business may be affected by various factors, including changes in market demand. Given the company’s broad product portfolio, the revenue associated with this business is not expected to have a material impact on the company’s overall financial performance. For more information about Sino Biological, visit www.sinobiological.com. For more information about Monod Bio, visit monod.bio.
